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THE EFFECTS OF OPIOID AND BENZODIAZEPINE WEANING ON COGNITIVE ABILITY IN THE
CONTEXT OF A CHRONIC PAIN REHABILITATION PROGRAM
DANIEL M. FISHMAN
ABSTRACT
Pain is a component of many disease processes; however in some cases, when pain becomes a
chronic condition it can become the problem itself. It can be a debilitating condition which is emotionally
and economically costly to the individual, his or her family, and societies as a whole. Theories of pain have
evolved over the last several decades to incorporate a Biopsychosocial Model of Pain. The biological
portion of the model relies on The Gate Control Theory of Pain, although some emerging research points to
a Neuromatrix model. As is suggested by the term, Biopsychosocial Model of Pain, the biologic basis of
pain is only a part of the overall phenomenon. The experience of pain relies on many subjective, individual
and environmental factors. Similarly the treatment of pain has evolved to encompass multiple dimensions
of the phenomena of pain. The predominant model of Interdisciplinary Treatment encompasses seven
areas: Medication; Education; Psychophysiologic Pain and Stress Management; Individual and Group
Psychotherapy; Physical and Occupational Therapy; Behavior Modification; and Family Therapy. While
classically medication with opioid analgesics and benzodiazepines has been a mainstay of treatment, they
have recently been the source of considerable debate. Some research and practitioners suggest that these
medications may hinder a patient’s progress in treatment and reduce or inhibit their functioning overall and
contribute to their pain. The exact nature of the relationship to neurocognitive functioning is still the source
of considerable debate. This paper examines the relationship of two classes of medication: opioids and
benzodiazepines to neurocognitive functioning as measured by two subtests of the WAIS-R (Digit Span &
Digit-Symbol

Substitution

Test)

in

a

Cleveland,

iv

OH

pain

rehabilitation clinic

population.
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CHAPTER I
INTRODUCTION AND SCOPE OF PROBLEM

Epidemiological and Economical Considerations
Pain is a component of many disease processes; however in some cases it is or
becomes the problem itself. It can be a debilitating condition bestowing both an
emotional and economical cost to the individual, his or her family, and societies as a
whole (Bonica, 1990; Gerdle et al, 1999; Gran 2003; Haythornthwaite & Benrud-Larson,
2001; McBeth, Jones, 2007; NIH, 1982; Robinson 2007). As Bajwa & Warfield stated,
"Throughout the world, chronic pain is the most frequent cause of suffering and disability
that seriously impair the quality of life" (2008 p2). A 2007 study in Britain found that
although specific rates vary due to differences in study methodology, pain is commonly
reported among adult populations, with almost one fifth reporting widespread pain, one
third shoulder pain, and up to one half reporting low back pain in a 1-month period
(McBeth & Jones, 2007). An additional study published in 2003 estimated that
approximately 10% of the general populations of North America and Europe report
1

chronic widespread musculoskeletal pain as a major health problem (Gran 2003). A 1982
National Institute of Health (NIH) publication stated that "chronic pain is the third largest
health problem in the world" (NIH, 1982). A Swedish study in 1999 found the prevalence
rates of current and chronic pain to be 49% and 54%, respectively, with current pain
defined as the respondent experiencing pain at the time of response and chronic pain by
the duration of pain (Gerdle et al, 1999). In 2003 The American Academy of Pain
Management (2003) asserted that approximately 57% of all adult Americans reported
experiencing recurrent or chronic pain in the past year; furthermore, approximately 62%
of these individuals reported being in pain for more than 1 year, and 40% noted that they
were constantly in pain (American Academy of Pain Management, 2003). Finally, as
noted recently by Gatchel et al: “pain is a pervasive medical problem: It affects over 50
million Americans and costs more than $70 billion annually in health care costs and lost
productivity; it accounts for more than 80% of all physician visits. Moreover, chronic
pain is often associated with major comorbid psychiatric disorders and emotional
suffering.” (2007, 2004a, 2004b).

Effects on Family
Beyond the societal costs of pain, an individual with chronic pain does not suffer
in a vacuum. His/her pain affects and is affected by all the members of the family.
Family, as used here, refers to the "primary units of mutual obligations that provide a
broad range of emotional and material support. They do not need to consist of blood
relatives nor do they have to be living together" (Dean, Lin & Ensel, 1981; Turk &
Kerns, 1985). In this construct the family is viewed as integral to the patient’s overall
2

health. As the primary unit of social interaction, the family aids in shaping the depth,
breadth and course of a patient’s symptomatology. This shaping occurs as a result of the
families’ definitions of appropriate reactions to illness, as well as which symptoms are
causes for concern and which are not (Dean et al., 1981; Haythornthwaite et al., 2001;
Lewandowski et al., 2007a; Lewandowski et al., 2007b; Nickel et al., 2008; Turk et al.,
2004; Turk et al., 2002). Furthermore, the family, along with the individual members in
it, suffers with the patient as a result of his/her pain. This suffering is both
empathetic/sympathetic suffering as well as suffering unique to immediate caregivers.
(Dean et al., 1981; Haythornthwaite et al., 2001; Lewandowski et al., 2007a;
Lewandowski et al., 2007b; Turk et al., 2004; Turk et al., 2002). The patient information
packets given to patient’s and family members of Cleveland Clinic Chronic Pain
Rehabilitation Program (CC-CPRP) states that family members often experience:
frustration, anger/irritability, anxiety/fear, guilt, loss of autonomy, helplessness, financial
losses, insecurity, depression, social isolation, and impaired quality of life (Baanders et
al., 2007; Burridge et al., 2007; Cano et al., 2006; CCF, 2007; Geisser et al., 2005;
Holtzman et al., 2007; Johansen et al., 2007; Leonard et al., 2006; Newton-John et al.,
2006; Pence et al., 2006). The first four items in the preceding list were reported as most
important to spouses of individuals with chronic pain as reported at the American
Chronic Pain Association Leaders Retreat in 1993. Furthermore, while the individual
with pain is aware of the family members' frustration and irritability, he or she may not
be aware of the guilt that often arises from misplaced self-blame on the part of the family
member (Dean et al., 1981; Haythornthwaite et al., 2001;Nickel et al., 2008;
Lewandowski et al., 2007a; Lewandowski et al., 2007b; Turk et al., 2004; Turk et al.,
3

2002) In addition, families of individuals with chronic pain will often report feeling
controlled by the individual's pain. Family members feel obligated to give much to the
individual with pain, while they may perceive they are receiving little in return. In
combination with the aforementioned guilt this can generate feelings of resentment and
result in a sense of hopelessness, and sometimes depression (Buenaver et al., 2007; Dean
et al., 1981; Haythornthwaite et al., 2001; Lemstra et al., 2005; Lewandowski et al.,
2007a; Lewandowski et al., 2007b; Nickel et al., 2008; Turk et al., 2004; Turk et al.,
2002).
The symptoms displayed by the families of those with chronic pain can vary and
include: nervousness and fatigue, moderate depression, and even empathetic physiologic
arousal in response to viewing the individual in pain (Buenaver et al., 2007; Dean et al.,
1981; Haythornthwaite et al., 2001; Nickel et al., 2008; Lemstra et al., 2005;
Lewandowski et al., 2007a; Lewandowski et al., 2007b; Turk et al., 2004; Turk et al.,
2002). Family members with this high degree of empathy are found to have higher
incidences of stress-related illnesses such as ulcers, headaches, and GI disturbances.
Interestingly, the most significant factor contributing to the families manifestation of
symptoms was not the individual's pain itself, but rather the individual's - and the families
- coping strategies for the pain (Baanders et al., 2007; Burridge et al., 2007; Cano et al.,
2006; Geisser et al., 2005; Holtzman et al., 2007; Johansen et al., 2007; Lemstra et al.,
2005; Leonard et al., 2006; Lewandowski et al., 2007a; Lewandowski et al., 2007b;
Newton-John et al., 2006; Pence et al., 2006; Schwartz et al., 2005; Turk et al., 2004;
Turk et al., 2002). This is exemplified by the preponderance of spouses who report that a
core issue of the chronic pain is the associated uncertainty and inability to assign meaning
4

to it (Baanders et al., 2007; Burridge et al., 2007; Cano et al., 2006; Geisser et al., 2005;
Holtzman et al., 2007; Johansen et al., 2007; Leonard et al., 2006; Newton-John et al.,
2006; Pence et al., 2006; Schwartz et al., 2005). While considering all of these effects of
the patient on the family, it is essential to keep in mind that this interaction proceeds in
both directions, that is the patient affects the family and the family affects the patient.
Families’ Reciprocal Effect on Patient's Pain
As was mentioned earlier, the family plays a large role in shaping an individual’s
illness. It defines appropriate reactions to illness, and largely defines which symptoms are
causes for concern and which are not. In fact studies have shown that spousal traits are a
strong predictor of treatment outcome with patients: spouses whose personality tests
indicate high levels of physical preoccupation, denial, and repression have worse
prognosis than those with spouses whose personality tests do not demonstrate these
qualities. Furthermore, families may exacerbate pain by effectively constituting stressors
in the patient’s life (Baanders et al., 2007; Burridge et al., 2007; Cano et al., 2006;
Geisser et al., 2005; Holtzman et al., 2007; Johansen et al., 2007; Leonard et al., 2006;
Newton-John et al., 2006; Pence et al., 2006; Schwartz et al., 2005). Lastly, and perhaps
most importantly, the family’s behaviors and responses to the patient’s behaviors often
plays a significant role in the patient’s recovery. Families of patients with chronic pain
are often the primary source of social interaction for that patient. Therefore, their well
intentioned caregiving may at times actually enable the continuation of pain behavior and
symptomatolgy. This is achieved through classical operant conditioning; a patient
receives greater reinforcement for pain behavior as opposed to non-pain behavior (Dean
et al., 1981; Lewandowski et al., 2007a; Lewandowski et al., 2007b; Turk et al., 2004;
5

Turk et al., 2002). This will addressed further when discussing multidimensional
treatment strategies for chronic pain.
As can be seen from the above discussion chronic pain results in decreased
quality of life for the patient and his/her family, as well as lost productivity and wages.
Unfortunately, in some cases it can also result in decreased length of life. Some patients
afflicted with pain come to believe that it is something which must be endured rather than
treated and reduced, and as a result some see suicide as their only way out (Bajwa &
Warfield, 2008). Given these myriad effects of pain on the lives of the patient, his/her
family, and society as a whole, any treatment(s) that can reduce the incidence or severity
of pain are greatly needed. Unfortunately, historically, the various forms of pain have
been undertreated despite significant interest in its study from both psychological and
physiological perspectives (Bajwa & Warfield, 2008). First I will examine several
theories of pain, most rooted in Melzack and Wall's gate control theory of pain (Melzack
& Wall, 1965). Then I will discuss the issues related to the undertreatment of pain.

6

CHAPTER II
TRADITIONAL APPROACHES TO PAIN: THE GATE CONTROL THEORY
OF PAIN

The Gate Control Theory of Pain states that the perception of pain arises not only
from a direct result of activation of pain receptor neurons, but instead is the result of a
complex interplay of neural signals from various sources. This is also referred to as the
Neural Basis of Pain. The pain signal originates in the periphery (Peripheral Nervous
System, or PNS) and is transmitted via afferent nociceptor fibers to the central nervous
system (CNS). There are two distinct types of nociceptor fibers: fast, relatively thick,
myelinated Aδ fibers that carry messages quickly with intense pain; and small,
unmyelinated, slow "C" fibers that carry the longer-term throbbing and chronic pain.
Superimposed on these nociceptor fibers are nonnociceptive large-diameter Aβ fibers that
can inhibit the effects of both types of nociceptors. This inhibition occurs in the PNS in
several areas of the spinal cord such as those in the dorsal horn referred to as laminae.
The net effect of these inhibitory Aβ fibers is to "close the gate" to the transmission
further upstream of the pain stimulus. It is this "gate closing" that gives rise to the term
7

"Gate Theory of Pain." In a further level of complexity, which has recently come to light,
the nociceptive fibers can, in other areas of the laminae, inhibit the inhibitory effects of
Aβ fibers, essentially opening the gate (Bajwa & Warfield, 2008; Kandel et al., 2000;
Melzack & Wall, 1965).
As mentioned in the above paragraph, afferent pain sensory neurons project into
the dorsal horns of the spinal cord; it is here where the initial gate control is thought to
occur. Furthermore, in the spinal cord these afferent projections meet with the
spinothalamicocortical (STC) tract which is responsible for the upstream transmission of
the pain signal. The STC tract transmits the pain stimulus from the PNS through the
brainstem, to various thalamic nuclei such as the ventroposteriolateral (VPL) nucleus,
and finally to cortical areas, such as the anterior cingulate cortex (ACC) as well as frontal
lobe areas (Albanese et al., 2007; Kandel et al., 2000; Kulkarni et al., 2005; Peyron et al.,
2000; Price, 2000; Rainville, 2002; Rainville et al., 2001; Rainville et al., 1997; Rome &
Rome, 2000; Simon et al., 2006).
The advent of new, less invasive technologies as well as appropriate animal
models has allowed for the study of the cortical projections, and relative activities of
various cortical areas in response to painful stimuli. These studies have yielded data that
demonstrate the involvement of several different brainstem and cortical areas in the
sensation of pain (Albanese et al., 2007; Kandel et al., 2000; Kulkarni et al., 2005;
Peyron et al., 2000; Price, 2000; Rainville, 2002; Rainville et al., 2001; Rainville et al.,
1997; Rome & Rome, 2000; Simon et al., 2006) One such study conducted in rat models
revealed a pathway in which the dorsal horn of the spinal cord projects to the dorsocaudal
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medulla (subnucleus reticularis dorsalis), then to the ventromedian (VM) nucleus of the
thalamus, and finally to the dorsolateral frontal lobes (Monconduit et al., 1999).
Similar studies have demonstrated the projection of afferent pathways to, and
involvement of cortical areas in, the affective aspect of pain. For example, studies have
demonstrated an ascending pathway from the spinal cord to the parabrachial nucleus
(Pb), which continues on to the hypothalamus and the amygdala (Bernard et al., 1996;
Bester et al., 2000). Other studies have suggested that nociceptive information may be
transmitted from the Pb to the intralaminar thalamus, and subsequently to the frontal
cortices (Bourgeais et al., 2001; Rainville, 2002). Finally, there is evidence of projections
from the Pb to the basal forebrain via the central nucleus of the amygdala (Rainville,
2002). Many of these cortical areas have been shown to be involved in aspects of emotion
and may therefore be involved in the emotional aspects of pain and their interactions with
cognitive processes (Kandel et al., 2000; Rainville, 2002).
Beyond simple reception of afferent, ascending pathways recent studies have
suggested that higher order brain structures can actually modify and modulate the
incoming signals (Rainville, 2002). For example, studies have demonstrated that the
periacqueductal gray (PAG) area plays a key role in descending mechanisms that
modulate spinal nociceptive activity (Fields, 2000; Price, 2000; Rainville, 2002). This
work follows studies demonstrating inputs to the PAG from areas such as the
somatosensory cortices, the insular cortex and the medial prefrontal cortex, including the
ACC (An X et al., 1998; Mantyh, 1982; Rainville, 2002). Moreover, in the case of the
ACC, descending projections are found from multiple areas including: Brodmann area
(BA) 25; BA32; and BA24b, the area that receives spinothalamocortical nociceptive
9

input (Rainville 2002). Taken together these studies support the hypothesis that the
overall experience of pain is not a passive phenomenon on the part of higher brain areas,
but rather these higher areas can exert influence over the perception. This suggests that
individuals can learn strategies (behavioral or cognitive) to effectively reduce the
experience of pain.

10

CHAPTER III
CLASSIFICATION OF PAIN

Nociceptive vs. Neuropathic Pain
One method used in classifying and potentially treating pain, has been to classify
pain, based on its stimulus, into either nociceptive or neuropathic pain (Bajwa &
Warfield, 2008; Casey & Lorenz J., 2003; Gilron et al., 2006; Haythornthwaite &
Benrud-Larson, 2001; Kandel et al., 2000; Martin & Saleeby, 2007; Melzak, 1993;
Moseley, 2003; Moulin et al., 2007). Here the term nociceptive is used to allude to the
nociceptive fibers of the PNS. Nociceptive pain is the perception of nociceptive input and
is usually attributed to direct tissue damage. It is further subdivided into: somatic pain which is pain that arises from damage to body tissues and is well localized but variable in
description and experience; and visceral pain - which is pain arising from the viscera and
is mediated by stretch receptors, poorly localized, and deep, dull, and cramping in nature
(Bajwa & Warfield, 2008; Kandel et al., 2000; Martin & Saleeby, 2007; Melzak, 1993;
Moseley, 2003).
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On the other end of this spectrum is neuropathic pain. This is pain arising from
abnormal neural activity secondary to disease or injury of the nervous system itself. This
pain remains persistent without ongoing disease (eg, diabetic neuropathy, trigeminal
neuralgia, or thalamic pain syndrome) (Bajwa & Warfield, 2008). Neuropathic pain is
further subdivided into the following: sympathetically mediated pain which is pain that
arises from a peripheral nerve lesion and is associated with autonomic changes (eg,
complex regional pain syndrome I and II [reflex sympathetic dystrophy and causalgia]);
nonsympathetically mediated pain which is due to damage to a peripheral nerve without
autonomic change (eg, post-herpetic neuralgia, neuroma formation); and central pain
which arises from abnormal central nervous system (CNS) activity (eg, phantom limb
pain, pain from spinal cord injuries, and post-stroke pain) (Bajwa & Warfield C. 2008;
Casey & Lorenz, 2003; Gilron et al., 2006; Haythornthwaite & Benrud-Larson, 2001;
Kandel et al., 2000; Martin & Saleeby L., 2007; Melzak, 1993; Moseley, 2003; Moulin et
al., 2007).
Acute vs. Chronic Pain
Another clinically useful, even necessary, classification of pain divides pain into
that which is acute or that which is chronic (Bajwa & Warfield, 2008; Kandel et al.,
2000; Robinson, 2007). This categorization is based primarily on temporal
considerations. Pain which occurs concurrent with or in close temporal relation to a
defining insult (physical or psychological), and resolves within a relatively brief period of
time, often arbitrarily defined as six months is considered acute. Acute pain is an
essential protective mechanism, which notifies us of potential dangers in our environment
(Bonica, 1990; Mersky, 1986; Woolf, 2004). This function is highlighted by the plight of
12

those afflicted with syndromes that render them incapable of sensing pain through the
congenital absence of nociceptors. These individuals are prone to self-injurious behavior
as well as continuous environmental injuries, often resulting in death at a young age (Cox
et al, 2006; Waxman, 2006).
In contrast to acute pain, chronic pain occurs with a loose temporal association to,
or a complete lack of association with, a defining insult or persists for a seemingly
unending period of time, once again often arbitrarily defined as greater than six weeks
(Bajwa & Warfield, 2008; Casey & Lorenz, 2003; Gilron et al., 2006; Haythornthwaite &
Benrud-Larson, 2001; Kandel et al., 2000; Martin & Saleeby, 2007; Melzak, 1993;
Moseley, 2003; Moulin et al., 2007). Put simply, chronic pain exceeds the ordinary
duration of time that an insult or injury to the body needs to heal, which is typically
thought of as four to six weeks (Bajwa & Warfield, 2008). Some researchers, however,
have extended this time frame to three months, labeling all pain shorter in duration as
acute (Bonica, 1990; Mersky, 1986). Despite the seemingly arbitrary nature of the time
frame, the distinction between acute and chronic pain is actually a crucial one. Pain
which surpasses the acute phase and proceeds to a chronic state may suggest a more
serious condition than originally thought, such as Complex Regional Pain Syndrome
(CRPS), and moreover may become a disease, of sorts, in and of itself (Bonica, 1990;
Mersky, 1986; Schmitt, 1985; Woolf, 2004).
A classification system for pain more complete than those described above has
been difficult to establish as pain is a component of so many processes and disease states
(Bajwa & Warfield, 2008). Furthermore, the experience and reporting of pain is a highly
subjective experience. Therefore, the International Society for the Study of Pain (IASP,
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1973) defined pain as "…an unpleasant sensory and emotional experience…" (Mersky,
1986). They envisioned a classification based along the following six axes: region
involved; systems involved; temporal characteristics; degree of intensity; time since
onset; and etiology (Bajwa & Warfield, 2008; Mersky, 1986). Adaptations of this scheme
are used daily in pain management clinics around the world (Bajwa & Warfield, 2008).
Even so, practitioners remain highly varied in the treatment of pain, prompting the search
for improved ways of understanding and treating pain.
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CHAPTER IV
NEW APPROACHES TO PAIN: NEUROMATRIX THEORY OF PAIN

The Gate Control Theory posited by Melzack and Wall has been used as a basis
for further research and theoretical development into both the physiologic and
psychologic basis of pain in order to aid in the development of treatment strategies. One
relatively novel theory is referred to as the Neuromatrix Theory of Pain. This theory
draws on, and emphasizes, the effect of central mechanisms on pain perception such as
those discussed above, that were found to be localized in a network connecting the
thalamus and the cortex, and the cortex and the limbic system (Albanese et al., 2007; An
X et al., 1998; Bittar et al, 2005; Fields, 2000; Kulkarni et al., 2005; Mantyh, 1982;
Monconduit et al., 1999; Peyron et al., 2000; Price, 2000; Rainville, 2002; Rainville et
al., 2001; Rainville et al., 1997; Rome & Rome, 2000; Simon et al., 2006). It proposes
that the perception of pain is generated by a "neuromatrix" which is genetically
determined and upon which environmental stimuli impinge (Melzack, 2005; Melzack,
2001; Melzack, 1999; Melzack, 1990; Mosley, 2003). This theory expands the body
schema idea to emphasize the intricate interplay of the conscious awareness of oneself
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and perceptual inputs (Giummarra, 2007). It states that the neuromatrix and environment
interplay, and combine over the course of an individual's life to generate a
"neurosignature" (Bittar et al., 2005). A crucial aim of the theory to help in the
explanation and development of possible treatment modalities of the phantom limb
syndrome wherein a limb that is no longer present is still perceived concomitant with
associated perceptual stimuli and pain (Bittar et al., 2005; Giummarra, 2007; Melzack,
2005; Melzack, 2001; Melzack, 1999; Melzack, 1990; Mosley, 2003).
The development of the Neuromatrix Theory of Pain has been spurred by an
overall progression from the medical model of diseases to the biopsychosocial model.
The Biopsychosocial Model emphasizes that illness, in contrast to disease, does not arise
or exist in a biologic vacuum. The environment and an individual's reaction to their
environment both physically and psychologically play an intricate role in the
development, progression and resolution of pathology and symptomatology (Gatchel et
al, 2007). Stated more simply: "disease is defined as an objective biological event
involving the disruption of specific body structures or organ systems caused by
anatomical, pathological, or physiological changes. In contrast, illness refers to a
subjective experience or self-attribution that a disease is present. Thus, illness refers to
how a sick person and members of his or her family live with, and respond to, symptoms
of disability" (Gatchel et al, 2007; Turk & Monarch, 2002). This distinction is analogous
to that between simple nociception, which refers to the physical/biologic/chemical
stimulation of nerves which then relay information further upstream in the nervous
system and an individual’s perception of pain, which is an amalgamation of the
nociceptive input as it is filtered through and combined with the individual's genetic
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composition, psychological state, and sociocultural influences (Gatchel et al, 2007).
Moreover, nociceptive transduction can be detected, via electrical conductance changes,
in anesthetized patients while, as far as is known, pain is not perceived while unconscious
(Gatchel et al, 2007). The realization inherent in this model, that pain is not a simple
biologic signal but a fluid, evolving, and individual-dependent phenomena, has been
crucial in the evolution of new treatment protocols, which are now evolving to address all
components of the pain experience and process. Moreover, as a result of the persistent
nature of chronic pain and it’s resistance to medical therapy alone, the biopsychosocial
model has had an even greater effect on its treatment.
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CHAPTER V
INTERDISCIPLINARY PAIN REHABILITATION MODEL (IPR MODEL)

The treatment of chronic pain has evolved to be a multidimensional,
interdisciplinary endeavor. Clinics devoted to the treatment of those with chronic pain
focus

their

treatment

in

several

areas

including:

medication;

education;

psychophysiologic pain and stress management; individual and group psychotherapy;
physical and occupational therapy; behavior modification; and family therapy (Andrasik
et al., 2007; Andrasik et al, 2005; Andrasik, 2003; Cano et al., 2006; Lemstra et al., 2005;
Nielson et al., 2001). Each of these modalities is meant to address components of the pain
process.
Medication. One of the most widely known in the lay population, and certainly
one of the most commonly used of the modalities for pain management, is medication.
The medications used in the management of chronic pain differ somewhat from those
used in the treatment of acute pain, and include but are not limited to: antidepressants,
antiepileptics, opioid analgesics, benzodiazepine tranquilizers, and barbituate sedatives.
Antidepressants are helpful in patients with diagnosed depression as well as those with
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depressive symptoms (Gilron et al., 2006; Martin et al., 2007; Moulin et al., 2007).
Antidepressants such as Effexor and Cymbalta have an effect on pain independent of the
antidepressant effect. Antiepileptics are useful in the treatment of a variety of forms of
intractable pain, but primarily in those whose etiology is that of disease of, or damage to,
nerves. The remaining three classes, opioids, benzodiazepines, and barbituates, are all
used to lessen the sensation of pain but can have significant neurocognitive side effects.
These classes of medication can significantly alter an individual's quality of life and may
even contribute, in the long term, to the worsening of the patient's pain through a variety
of mechanisms including opioid induced hyperalgesia. Therefore, weaning from the long
term use of these types of medications has become an important part of Interdisciplinary
treatment programs. In fact, patients receiving treatment in the CC-CPRC are weaned
from both opioids and benzodiazepines over the course of their treatment.
Education. Education is a critical component of an individual's treatment. Patients
need to be shown that they have been thoroughly evaluated, and listened to. Moreover,
they need reassurance that their pain does not necessarily indicate that something
catastrophic is happening to their body. Patients need to understand what treatment
outcomes are and are not possible, that is which symptoms can be treated and which
cannot.
Psychophysiologic Pain and Stress Management. Psychophysiologic Pain and
Stress Management involves the learning of techniques to reduce physiological arousal in
a pain experience. These strategies teach an individual how to reduce muscle tension and
enhance hand temperature control as well as reducing overall physiological arousal by
reducing palmar sweating utilizing biofeedback. Biofeedback involves the use of
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electrical conductance nodes, similar to those used in electrocardiography, which are
attached to the individual. These nodes relay electrical conductivity changes in epidermal
and muscle tissue to a computer which translates these changes into a graphic or
numerical display. This display is then used by the individual for self-monitoring of
progress while practicing various relaxation techniques. This allows an individual to relearn concrete behavioral methods for self-relaxation. These techniques can then be used
as a non-chemical method of stress reduction and self-relaxation. Moreover, they
demonstrate, in a real and tangible way to the patient, the effects of emotion on a body's
physiologic state (Andrasik et al., 2007; Andrasik, 2003; Astin, 2004; Astin et al., 2003;
Bruehl et al., 2006; Flor et al., 2007; Haythornthwaite et al., 2001; Mayo Clinic Health
Letters, 2007; Nestoriuc et al., 2007; Nielson et al., 2001; Stanos et al., 2006; Trautmann
et al., 2006).

Individual and Group Psychotherapy. Individual and Group Psychotherapy are
key components of treatment. Issues of depression and anxiety are commonly associated
with physical complaints often including pain, and individual psychotherapy can be used
to address these as well as other important issues. Confronting and coping with these
issues as well as others will often result in a reduction of symptoms of pain. The most
common psychotherapy techniques utilized in this setting are Cognitive-Behavioral in
orientation (Andrasik et al., 2007; Boothby et al., 2004; Bruehl et al., 2006; Buenaver et
al., 2008; Flor et al., 2007; Hoffman et al., 2007; Haythornthwaite et al., 2001; Kerns et
al., 2006; Lemstra et al., 2005; Menzel et al., 2006; Molton et al., 2007; McCracken et al.,
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2002; Nielson et al., 2001; Osborne et al., 2006; Thorn et al., 2007; Thorn et al., 2006;
Trautmann et al., 2006; Turner et al., 2006; Vowles et al., 2007).

Cognitive-Behavioral Therapy (CBT) is based on modifying cognitions,
assumptions, beliefs and behaviors in order to influence disturbed emotions. It states that
a person's core beliefs, which are often formed in childhood, contribute to automatic
thoughts that involuntarily “pop up” in everyday life in response to situations.
Additionally, individualized and patterned behaviors which serve to perpetuate, or
possibly cope with, these automatic thoughts develop. These automatic thoughts and
behaviors form a cycle of reinforcement. Therefore, therapy typically involves: the
identification and challenge of irrational or maladaptive thoughts, assumptions and
beliefs that are related to debilitating negative emotions, as well as associated behaviors.
Furthermore, since behavior is know to reinforce and help shape thought, patients are
engaged in behavioral skills training to aid in their struggle to overcome these engrained
patterns. In the case of a patient with chronic pain, these automatic thoughts as well the
associated behaviors and feelings of depression, helplessness, anxiety, and anger are
thought to exacerbate the pain the patient experiences. The mechanism of this
exacerbation may be purely psychological or, as newly emerging evidence (discussed
above) suggests, may reflect a modulatory effect of higher brain centers on the
experience of pain (Boothby et al., 2004; Breuhl et al., 2006; Buenaver et al., 2008; Cano
et al., 2006; Gallagher, 2005; Grazebrook et al., 2005; Holtzman et al., 2007; Kerns et al.,
2006; Lemstra et al., 2005; Molton et al., 2007; McCracken et al., 2002; Pence et al.,
2006; Thorn et al., 2007; Thorn et al., 2006).
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.

Once identified the client and therapist work together to reveal how these

automatic thoughts are dysfunctional, inaccurate, or simply not helpful. This is done in an
effort to reject the distorted cognitions and to replace them with more realistic and selfhelping alternatives (Boothby et al., 2004; Buenaver et al., 2008; Holtzman et al., 2007;
Leonard et al., 2006; Pence et al., 2006; Vowles et al., 2007; Turner et al., 2001). The
therapeutic techniques utilized vary according to the particular kind of client or issue, but
commonly include: keeping a diary of significant events and associated feelings, thoughts
and behaviors; questioning and testing cognitions, assumptions, evaluations and beliefs
that might be unhelpful and unrealistic; gradually facing activities which may have been
avoided; and trying out new ways of behaving and reacting. Relaxation and distraction
techniques are also commonly included (Boothby et al., 2004; Breuhl et al., 2006;
Buenaver et al., 2008; Gallagher, 2005; Grazebrook et al., 2005; Kerns et al., 2006;
Lemstra et al., 2005; Molton et al., 2007; McCracken et al., 2002; Thorn et al., 2007;
Thorn et al., 2006).

In the setting of the IPR clinic, various combinations of these techniques are used.
Patients may be asked to keep a log of negative thoughts as well the refutations. Utilizing
biofeedback methods, patients are taught how to reduce physiologic arousal related to
anxiety and depression, which are states known to exacerbate pain symptomatology.
Additionally, group therapy is employed to allow the patient to relate to others as a
person and not simply as someone in pain. This allows the patient to be supported by and
in turn offer support to peers, both of which are powerfully therapeutic. Support of one's
peers lets an individual know that they are not alone in what they are experiencing, while
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being able to support others allows a patient to use his pain - a condition which has likely
hampered his/her ability to contribute - to help others. The realization that, as a person
with pain, one is still able to significantly contribute to the lives of others in a positive
way is empowering and helps to combat the sensations of hopelessness and uselessness
which are often connected with, and indeed exacerbate, chronic pain (Hoffman et al.,
2007; Lemstra et al., 2005; Nielson et al., 2001; Thorn et al., 2006).

Behavior Modification. Behavior modification techniques, following the
operant conditioning model, are prevalent throughout every aspect and within every
patient-staff interaction in an Interdisciplinary approach. Most patients and their families
have fallen into a pattern of reinforcing sick behavior on the part of the patient.
Furthermore, most often in the medical model the patient who complains the most
receives the most attention; this serves to reinforce and perpetuate painful subjective
states and associated pain-related behaviors on the part of the patient. These pain-related
behaviors can be broadly defined as behaviors which exemplify or perpetuate a sick role
on the part of the patient. They may manifest in any number of ways, for example: the
patient’s unwillingness to perform activities which he/she is capable of and is either
required to do, or more tragically, actually enjoys; the patient may complain of or,
actually or subjectively experience increased levels of pain because family members then
afford the patient extra attention. A further secondary gain from pain related behaviors
may be additional medication.

Interdisciplinary Chronic Pain Rehabilitation models work to overturn this
tendency and reinforce positive, non-pain related behaviors. Patients are, of course,
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informed of this aspect of care so as to avoid deception. In its manual for new patients
The Cleveland Clinic Pain Rehabilitation Program (2007) explains that to avoid
deception, participants are informed that staff will respond positively to: their successes;
their communications about feelings; and all behaviors incompatible with the sick role.
Additionally they will attempt to ignore pain behaviors. This contrasts with the usual
medical situation where the patient who appears comfortable may be ignored while the
one who complains loudly will have a great deal of support. By reinforcing non-pain
related behaviors and attempting to ignore pain-related ones the Interdisciplinary
approach employs classic operant conditioning to promote change within the patient. This
change is not completely conscious: by decreasing the reinforcement for pain behavior
and increasing the reinforcement for non-pain behavior the entire subjective experience
of pain can be lessened (Buenaver et al., 2008; Gallagher, 2005; Hoffman et al., 2007;
Lemstra et al., 2005).
.

Family Therapy. Another component of the Interdisciplinary approach is Family

Therapy. As has been mentioned and alluded to above, the family is the primary unit of
social interaction for the patient and as such, helps to shape illness (Dean et al., 1981;
Haythornthwaite et al., 2001; Holtzman et al., 2007; Johansen & Cano, 2007;
Lewandowski et al., 2007a; Lewandowski et al., 2007b; Nickel et al., 2008; Turk et al.,
2004; Turk et al., 2002; Turk & Kerns, 1985). The importance of the family is perhaps
best demonstrated by the fact that the entire pain management program is likely to fail
without the involvement of the patient's family (Lewandowski et al., 2007a;
Lewandowski et al., 2007b; Nickel et al., 2008). It is the natural tendency of the family to
direct attention to problem areas while simultaneously not directing as much attention to
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non-pain related behaviors. As was mentioned in the section on behavior modification,
reinforcement of the sick role will increase pain-related behaviors and actually prevent
recovery. Therefore, the family must be educated as to its role in the perpetuation of pain
related behaviors and the sick role in the patient. This awareness is then augmented with
the principles of operant conditioning as well as its application to the individual and
family with chronic pain.
Physical and Occupational Therapy. Physical and Occupational Therapy are also
utilized in the treatment of chronic pain; however unlike in the treatment of acute pain,
staff do not use heat lamps, massages, ultra sound or other treatments directed at
immediate reduction of pain and inflammation. Rather, an active exercise program is
developed which

emphasizes general conditioning, posturing, flexibility, and

strengthening specific areas of deficit (Lemstra et al., 2005; Robinson, 2007). Key to the
approach is the pace at which therapy begins and proceeds. Therapy, and the associated
exercise program, are begun at levels which are easily accomplished by the patient. This
serves to offer positive reinforcement for not only the exercise itself, but perhaps more
importantly it offers positive reinforcement for a non-pain driven behavior. The patient is
able to step outside the sick role and receives positive reinforcement for it. As will be
seen shortly this is another important aspect of therapy (Gallagher, 2005; Lemstra et al.,
2005; Stanos et al., 2006).
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CHAPTER VI
INTERDISCIPLINARY PAIN MANAGEMENT OUTCOME DATA

Numerous studies have shown that the Interdisciplinary approach is effective in
the treatment of chronic pain (Hoffman et al., 2007; Hooten et al., 2007a; Hooten et al.,
2007b; Jensen et al., 2007; Kitahara et al., 2006; Lemstra et al., 2005; Moss-Morris et al.,
2007; Osborne et al., 2006; Stanos et al., 2006; Vowles et al., 2007). One recent study
conducted in Japan, a country in which there had yet to be established a Interdisciplinary
pain treatment program, found that "an interdisciplinary treatment based upon the
biopsychosocial model of pain was associated with significant improvement in multiple
outcomes" (Kithara et al., 2006). Additional studies, such as those by Stanos et al., (2006)
have utilized "return-to-work" as an outcome variable and found that Interdisciplinary
pain management increases a patient's ability and likelihood of returning to work. Some
studies have indicated a difference in outcomes between genders (Gran, 2003), however,
other studies have found improvement in both genders and that differences between
levels of improvement were consistent with differences in pre-trial measures (Hooten et
al., 2007a; Katz et al., 1990; Newton-John et al., 2006;). Finally, a 2005 study conducted
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by Lemstra et al. found not only positive health-related outcomes with Interdisciplinary
management, but also found the treatment to be economically sound and low-cost.
In examining the psychotherapeutic portion of Interdisciplinary treatment, Jensen
et al. (2007) examined the role of cognitions in treatment of chronic pain and found that
pain-related beliefs and coping responses were key factors in determining long-term
patient pain and adjustment. Similarly Hoffman et al. (2007) examined a group of
patients with Chronic Low Back Pain (CLBP) and found that "Interdisciplinary
approaches that included a psychological component, when compared with active control
conditions, were also noted to have positive short-term effects on pain interference and
positive long-term effects on return to work" (Hoffman et al. 2007). Vowles et al. (2007)
found the cognitive variables of acceptance and catastrophizing accounted for significant,
and approximately equal, portions of the variance in positive outcomes (Vowles et al.,
2007). Another study found that change in cognitive processes accounted for 26% and
23% of the improved physical and emotional functioning, respectively (Moss-Morris et
al., 2007).
Studies have also demonstrated that Interdisciplinary pain rehabilitation may
facilitate withdrawal from analgesic medication. Hooten et al. (2007b) examined a group
of Fibromyalgia (FM) patients and found that "post-treatment measures of physical and
emotional functioning are favorable for patients with FM following Interdisciplinary pain
rehabilitation that incorporates withdrawal of analgesic medications" (Hooten et al.,
2007b). The ability of the Interdisciplinary approach to allow the patient to withdraw
from analgesic medication is of significant benefit, given the numerous problematic side
effects attendant to use of these medications.
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Side Effects of Medication
Two classes of medication used in the Interdisciplinary Pain Management Model,
opioid analgesics and benzodiazepine tranquilizers, may have significant undesired
effects. In fact, these two classes of medications, while prescribed to provide analgesia
may in fact impair overall functioning of the patient and lead to opioid induced
hyperalgesia. A review of recent literature, however, demonstrates that the presence and
degree of impairment is still controversial.
Opioids. Opioids are a group of medications defined as having an effect on the
body similar to that of morphine. The mechanism of action of Opioids is mediated by the
opioid receptor which is found primarily in the Central Nervous System (CNS), and the
Gastrointestinal (GI) tract. Opioids can be divided into: natural (those occurring in
nature); semi-synthetic (naturally occurring opioids that have been chemically modified);
fully synthetic; and endogenous. The term opiate is often used interchangeably with
opioid; however it more properly refers to the natural and semi-synthetic opioids only.
While the opioids have a long standing history as useful analgesics, there are known
significant side effects that may inhibit a patient’s functioning including nausea,
vomiting, constipation, and cardiovascular effects (Bajwa & Warfield, 2008).
Additionally, there is the not so rare phenomenon of opioid induced hyperalgesia,
whereby the patient experiences increased pain in response to opioid administration
(Vella-Brincat et al., 2007; Wilson et al., 2003). Finally, opioids may produce sedation,
somnolence, mental clouding, addiction/dependence and it is theses phenomena that are
of greater concern, interest, and debate in this context.
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Cognitive dysfunction related to opioid use has been widely researched; however
this research is somewhat contradictory. One study found that "Long-term opioid therapy
produces a slight (non significant) impairment of psychomotor performance in patients
with cancer pain or non-malignant chronic pain. These effects become significantly more
pronounced with increasing age and in patients with cancer pain, indicating a higher
susceptibility of the elderly towards opioids…..However, since opioid effects were only
minimal in the non-elderly other factors like basic disease, opioid dose, physical
condition and age seem to be of greater importance than the effects of opioids per se."
(Larsen et al., 1999 p613). Another study, which focused on patients with non-malignant
pain found "Some aspects of psychomotor performance (reaction time, Digit Symbol
Substitution Test and Maddox Wing) were impaired by morphine; however, eye-hand
coordination was not. Miosis was induced by morphine. Most effects of morphine were
dose-related, some effects peaked soon after morphine injection (e.g., increased
stimulated and high ratings) and dissipated gradually, whereas other effects did not peak
until later into the session (sedation or exophoria)" (Zacny et al., 1994 p1). Additionally,
there is further evidence that sedation and cognitive dysfunction, somnolence and mental
clouding are common both at the onset of treatment and as the dose is escalated (Bajwa &
Warfield, 2008). There have also been reports of opioid induced neurotoxicity in some
patients; however this phenomenon is still controversial (Lawlor & Bruera, 1998; Zhang
et al., 2008). The mechanism of this neurotoxicity is similarly not well established but is
thought to involve induction of apoptotic cell death in neuronal and glial cells (Zhang et
al., 2008). However, there are also studies which suggest that although the subjective
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reports of cognitive impairment increase with opioid use, objective cognitive measures do
not always confirm this (Ersek et al., 2004).
Benzodiazepines. Benzodiazepines are a group of medications whose chemical
structures consist of a fusion of benzene and diazepine rings. They are psychoactive
drugs considered to be minor tranquilizers, with hypnotic, sedative, anxiolytic,
anticonvulsant, muscle relaxant and amnesic properties. These properties are mediated
either by depressing or stimulating the central nervous system via modulations of the
Gamma-aminobutyric acid A (GABAA) receptor, the most prolific inhibitory receptor
within the brain. Benzodiazepines are metabolized both hepatically, by the cytochrome
P450 (cP450) system, and renally via conjugation (Beers, 2006; Dupont et al. 2008;
Hardman et al., 2001). In the chronic non-malignant pain population, benzodiazepines are
often used in patients that would benefit from anxiolytic treatments. The primary
disadvantages of this class of medications are: their addictive potential; potentiation of
sedative effects such as those observed in combination with alcohol; and respiratory
depression when used in conjunction with opioids (Bajwa Warfield & Wootton, 2008).
Interdisciplinary Rehabilitation Programs can facilitate weaning of these
medications (Hooten et al. 2007; Kitahara, 2006). For a variety of reasons such as cost
and frequency of side effects, lessening the medication burden on a patient is generally a
sought after goal in all fields of healthcare. As the discussion above highlights, opioids
and benzodiazepines - mainstay components of pain management - carry significant side
effect profiles. Significant among their side effects, these two classes of medication are
thought to potentially slow or alter mentation; however there is still considerable debate
in the literature (Byas-Smith et al., 2005; Davis et al., 2007; Escher et al., 2007; Jamison
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et al. 2003; Kurita et al., 2008; Lintzeris et al., 2007; Mintzer et al., 2002; Rome et al.,
2004). The study described here utilized the patient database of Cleveland Clinic Chronic
Pain Rehabilitation Clinic (CC-CPRC) in Cleveland, OH to examine the relationship of
these classes of medication to two indices of cognitive function, Digit Span and Digit
Symbol Coding. These two measures are frequently used in the literature to examine the
effects of pharmacologic agents on cognitive functioning (Buckalew et al., 2008; ByasSmith et al., 2005; Escher et al., 2007; Haavisto et al., 2002; Kanof et al., 1992; Kurita et
al., 2008; Lintzeris et al., 2007; Mintzer et al., 2002; Ryhanen et al., 1978; Wang et al.,
2007).
The CC-CPRC has maintained a database with a wide array of data on all of its
patients since 1999. This study utilizes statistical methods, described below, to examine
the relationships of each class of medication to the level of cognitive functioning pre and
post-treatment in the clinic while simultaneously controlling for various demographic and
confounding variables. Based on the literature review just described and the
preponderance of anecdotal evidence it is expected that an individual’s neurocognitive
function, as measured by DS and/or DSST, will improve when opioid and/or
benzodiazepine therapy is withdrawn.
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CHAPTER VII
METHODS

Participants
The population contained in the database is quite large, consisting of all the
patients seen in the clinic since 1999; however this study utilized data from only one
year, 1999. The age, gender, socioeconomic (SES), marital status, and education level
distributions are all similarly large and diverse. As the CC-CPRC database is extensive
and contains data (pre & post-treatment measures of mood, functioning, pain intensity,
and cognitive functioning) on all patients covering their entire course in treatment as well
as follow-up data up to one year post-treatment, no additional data collection was
necessary. The average duration of treatment was three weeks. The crux of the research
discussed here relies on a re-evaluation of the patient database. The data culled form the
database includes: demographic information; medical diagnoses; mood assessed via Beck
Depression Index (BDI), Level of Functioning assessed via Pain Disability Index (PDI),
Pain Intensity assessed via self-report Likart scale (1-10), pre-treatment and post-
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treatment medications; Digit Span (DS) and Digit Symbol Substitution Test (DSST)
scores. A total of 225 participants’ information were used for this study.
Measures
At the onset of treatment, a thorough medical history is taken from each patient at
the CC-CPRC covering many different aspects of their medical history, pain, associated
disability, family, personal, and professional life. The BDI, PDI, Digit Span and Digit
Symbol Coding measures are also administered. As with many clinics, the patients are
given background demographic and medical history forms to fill out on their own prior to
being seen in the clinic. This is followed by a thorough intake history taken collectively
by members of the clinic staff (Physicians, Psychologist, Fellows and Nurses). This
information is kept in the patient’s medical records. The Digit Span and Digit Symbol
Coding measures were administered by psychology assistants and post-doctoral
psychology fellows. All of these assessments are then repeated upon discharge from the
clinic. These data are kept on secure computers at the facility.
The Beck Depression Index (BDI; Beck 1996a) is a well-researched, widely
accepted, and brief clinical assessment of depression. It reflects the client’s state over the
last several weeks (Ambrosini et al., 1991; Beck et al., 1996a; Beck et al., 1996b; Cohen
A, 2008; Dworkin et al., 2008; Feightner, 1990; Groth-Marnat, 2003; Lykke, 2008;
Naughton & Wiklund, 1993; Osman et al., 2008; Roth et al., 2005; Segal et al., 2008;
Seignourel et al., 2008; Steer et al., 1999; Storch et al., 2004). It consists of a 21 question
self report inventory designed for individuals aged 13 and over. It is composed of items
relating to symptoms of depression such as: hopelessness and irritability; cognitions such
as guilt or feelings of being punished; as well as physical symptoms such as fatigue,
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weight loss, and lack of interest in sex (Beck, 1972). Each response is scored on a scale
of 0 to 3, summed inventory scores are then divided into classes of, or degrees of,
depression: 0–13: minimal depression; 14–19: mild depression; 20–28: moderate
depression; and 29–63: severe depression. Higher total scores indicate more severe
depressive symptoms. It is also thought that total scores less than 4 likely reflect an
intentional shaping of the results by the examinee (Groth-Marnat, 2003).
The BDI has been shown to positively correlate with the Hamilton Depression
Rating Scale (r=0.71) It was also shown to have a high one-week test–retest reliability (r
=0.93), suggesting that it was not overly sensitive to daily variations in mood (Beck et al.,
1996a). A high internal consistency (α=.91) has also been shown (Beck et al., 1996b).
The Pain Disability Index (PDI; Pollard, C. A., 1984; Richards et al., 1982; Tait et
al., 1987) is a seven item, self-report inventory designed to measure the effect of an
individual’s chronic pain on his or her daily life. The assessment spans seven domains:
family/home responsibility; recreation; social activity; occupation; sexual behavior; selfcare; and life support activity. Individuals are asked to select the level of impairment
perceived in each domain as a result of their pain. Each item ranges from 0 or no
disability to 10 or total disability, the sum of all seven items is then used to generate an
overall score ranging from 0 to 70, with larger scores reflecting greater disability
(Chibnall & Tait, 1994; Gatchel, R. J., & Okifuji, A., 2006; Jerome, A., & Gross, R. T.,
1991; Pollard, C. A., 1984; Richards et al., 1982; Stanos, S., & Houle, T. T., 2006; Tait et
al., 1990; Tait et al., 1987).
The validity of the PDI has been demonstrated numerous times. Pollard (1984)
showed that the PDI could discriminate between low and high disability groups, while
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Tait et al. (1987) demonstrated that inpatients score higher than outpatients. Several other
studied have also examined the PDI’s construct validity and found it to be sound (Jerome
& Gross, 1991; Tait, Chibnall, & Krause, 1990). Additionally, Gronblad et al (1993)
examined inter-correlations between the PDI and the Oswestry Disability Questionnaire
and found high correlations between raw scores (r = 0.83), factor scores (r = 0.84), and
percentage scores (r = 0.82).
An individual’s Pain Intensity was assessed by subjective self report. The patient
was asked to rate their current level of pain intensity on a scale of 0 or no pain to 10 or
unbearable pain at both onset and cessation of treatment.
The Digit Span (DS) and Digit Symbol Substitution Test (DSST) are wellresearched, empirically validated, widely used, and brief assessments of intellectual
functioning. They are components of the Wechsler Adult Intelligence Scale – III Revised
(WAIS-IIIR) and have been used extensively in the literature in studies similar to this
which examine the neurocognitive effects of various pharmacologic agents (Buckalew et
al., 2008; Byas-Smith et al., 2005; Escher et al., 2007; Haavisto et al., 2002; Kanof et al.,
1992; Kurita et al., 2008; Lintzeris et al., 2007; Mintzer et al., 2002; Ryhanen et al., 1978;
Wang et al., 2007).
The Digit Span is considered a measure of Verbal Intelligence and is composed
two broad parts: random number sequence repetition; and reverse random number
sequence repetition. Each portion is composed of 2 item trials which begin with a short (2
number width) sequence that builds to longer and longer sequences as the examinee
obtains correct responses and the items progress. The forward repetition portion serves as
a measure of memory capacity. It also serves a secondary function as a control for the
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reverse repetition portion of the test. The reverse portion of the test requires additional
cognitive ability as it necessitates both memory of the sequence and the ability to
maintain that memory while performing a cognitive function on the set, reversal. The DS
is scored as 1 point per sequence trial, examinee self corrections are given credit. The
examiner is also able to note certain behaviors such as strategies the examinee uses to
complete the task. The test is terminated after the examinee receives a score of 0 on each
of 2 trials on any given item or when all items are administered. The reverse sequence
portion of the test is administered even if the examinee is unable to complete any of the
forward response items (Kaufman & Lichtenberger,1999).
The DSST is considered a measure of Performance Intelligence and is a timed
task with a limit of 120 seconds. The examinee is given a DSST form and asked to
complete as many rows as possible in the allotted time, by pairing the correct symbols
with the correct numbers. The test is scored simply by giving 1 point for each correct
pairing. The examiner is also able to note associated task behaviors and strategies. This
task draws on the examinee’s memory, concentration and visuomotor coordination
(Kaufm
an

&

Table 2 WAIS-III Overall and Subtest Reliability
Spilt Half
Test-Retest
WAIS-III Scale, Index or Subscale
Reliability
Reliability

Lichten
Verbal IQ (VIQ)

0.97

0.96

Performance IQ (PIQ)

0.94

0.91

Full Scale IQ (FSIQ)

0.98

0.96

Digit Span (DS)

0.90

0.83

-

0.86

berger,
1999).

The DS

Digit Symbol Substitution Test
(DSST)
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and DSST were found to have ample specificities (0.50/0.10 and 0.38/0.16 respectively
where the first value in each pair represents the reliable unique variance of the subtest
while the second value represents the subtest error variance) in accounting for variance of
WAIS-III IQ scores (Kaufman & Lichtenberger, 1999 p80). It is therefore possible to use
them as a basis for inference of Verbal (VIQ), Performance (PIQ) and Full Scale (FSIQ)
as measured by the WAIS-III. Overall the WAIS-III has demonstrated good validity
when compared to other measures of intelligence with correlations of: 0.64 with Standard
Progressive Matrices; and 0.88 with the Stanford-Binet-IV Composite (Kaufman &
Lichtenberger, 1999 p168). Additionally, reliability of the DS, DSST and overall of the
WAIS-III, in assessing IQ were excellent (See Table 1 - (Kaufman & Lichtenberger,
1999 p12).
All the data collected are stored in secure facilities and computers at the
CCFCPRC. At no time was data removed from the clinic facility or accessed from nonsecure computers.
Research Design
The design utilized here is that of a retrospective analysis of collected data. The
effects of two classes of medication (opioids and benzodiazepines) on pre-treatment and
post-treatment neurocognitive indices (Digit Span (DS) and Digit Symbol Substitution
Test (DSST)) were assessed. Participants were divided into four cohorts: Cohort 1 –
Neither opioids or benzodiazepines at the onset of treatment (n= 83); Cohort 2 – opioids
only at the onset of treatment (n= 81); Cohort 3 – benzodiazepines only at the onset of
treatment (n= 22); Cohort 4 – both opioids and benzodiazepines at the onset of treatment
(n= 39): In addition, Cohort 5 – a union of Cohorts 1 -4, was used in the analysis for
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overall treatment efficacy (n= 225). All participants who initiated treatment while taking
opioids or benzodiazepines were completely weaned at the end of the 3-week treatment
course. Any participant who did not complete treatment, or left against medical advice
(AMA), was disqualified from the analyses.
In examining the effects of these medications several potential confounding
factors were examined: Mood – assessed with the Beck Depression Index (BDI), Level of
Functioning – assessed with the Pain Disability Index (PDI), and Pain Intensity –
assessed via self-report Likart (0-10). As an initial step, preliminary comparisons were
made with simple Pearson correlations. These Pearson correlations were confined to
comparisons of admit v admit, discharge v discharge, and change v change data for each
cohort. Tables describing these analyses and summarizing their results may be found in
Appendix A Tables 1 thru 5.
After the preliminary analyses were conducted, the effects of confounds were
isolated and assessed primarily through a Hierarchical Multiple Regression strategy. The
confounds: ∆ Mood (∆ BDI); ∆ Functionality (∆ PDI); and ∆ Pain Intensity where
entered as blocks (independent variables, IVs) in the Hierarchical Multiple Regression
model, while ∆ DS scaled score and ∆ DSST scaled score were used as separate outcome
measures (dependent variables, DVs). Their order of entry of the IVs was varied so that
each DV occupied each spot in the entry order sequence. As mentioned above, this
method of analysis can isolate contributing variance portions from each confound and
determine significance. Furthermore, varying the order of entry of the DVs was employed
based on theoretical predictions that these DVs were thought to have overlapping
variances, which may cause the model to generate different values for the individual
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DV’s variances and significance levels based on order of entry. This first Hierarchical
Multiple Regression strategy, shown in Appendix A Table 6, demonstrates the
confounding variables’ contribution to variance in the IVs in each individual cohort.
A second Hierarchical Multiple Regression strategy was also used to assess the
effect of Cohort membership on outcome variables. As will be discussed below, the first
Hierarchical Multiple Regression analysis demonstrated that the variance in either IV due
to each confound was not dependent on entry order, therefore in constructing the second
Hierarchical Multiple Regression entry order of these three confounds was not varied. In
this second analysis cohort membership was dummy coded (Cohort 1=1, Cohort 2=2,
Cohort 3=3, Cohort 4=4, and Cohort 5=5). The order was entry was varied insofar as the
point at which Cohort membership was entered was varied. This strategy allows for the
assessment of effect of cohort membership on the variance in the IVs. In plain English,
this translates to an analysis of the effect of medication status (opioid or benzodiazepine
status) on the neurocognitive measures DS and DSST. These results can be found in
Appendix A Table 7.
Finally, two MANOVA strategies were employed as parallel and re-enforcing
analyses. These MANOVA strategies were used to look for both: differences in changes
(post-pre treatment) in neurocognitive measures between cohorts; as well as pre and post
treatment changes within each cohort. Tables depicting the MANOVA analysis strategies
can be found in Appendix A Table 8. Summary tables for the MANOVA analyses may
also be found in Appendix A, Tables 9 and 10.
Several known confounds were not explicitly assessed in these analyses, such as:
demographic variables, and dosage of medication. It was reasoned that since participants
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were not pre-screened from the clinic population, and all participants had an equal chance
of arriving at the clinic fitting the criteria of one of the cohorts, the cohorts formed would
be sufficiently diverse such as to negate a prejudicial effect of any given demographic
variable. Dosage of medication was not controlled for because effective dosages vary
greatly across a population and are affected by many confounds themselves, such as age
and Body Mass Index (BMI). A given dosage will mean entirely different effects for
different patients. Therefore it is the overall effect of a medication on a patient assessed
by comparing neurocognitive functioning while taking and while not taking a given
medication that is assessed here.
As patients begin treatment at CC-CPRP while: 1. on neither opioid or
benzodiazepine therapy; 2. on opioid therapy; 3. on benzodiazepine therapy; or 4. on both
opioid and benzodiazepine, and 100% have been weaned from these medications at
discharge, the neurocognitive assessments used to determine functioning on medication
were given at admission to the program and those used to assess neurocognitive
functioning off of medication therapy were given at discharge from the program. Cohort
1, those who were never on opioid or benzodiazepine therapy will be used as a control
cohort.
Data Analysis
All data analysis was conducted at the CC-CPRC. At no time was data removed
from the facility.
Multiple Regression analysis is a well-established, widely used, and efficient
method for elucidating effect sizes while simultaneously controlling for many possible
confounds. It dates back to Pearson in 1908, and in short, works to assign variances to
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any of a number of independent variables. These variances represent the amount of
variability in the dependent variable accounted for by the given independent variable(s).
For example, in this case, the Multiple Regression analysis has assigned a certain
percentage of the variance in neurocognitive functioning to the confound variables
described above, thereby illuminating any statistically significant contributions of those
confounds to the change in neurocognitive functioning (See Appendix A Table 6 and
Appendix B Tables 1.1 to 5.6). It was also able to assess the effect of cohort membership
as a predictor for changes in neurocognitive measures (See Appendix A Table 7 and
Appendix B Tables 6.1 to 6.8) (Hair et al., 2006).
The MANOVA (Multiple Analysis of Variance) looks for significance in the
effect of the chosen independent variable(s), in this case Mood, Functioning, Pain
Intensity, and Cohort Membership on the dependent variables, in this case the DS and
DSST. If a significant effect is found, univariate F-tests can then be performed to
elucidate more specifically where the significance lies. MANOVA can be performed in
either a between groups or repeated measures paradigm. In this case, the between groups
paradigm was utilized to comment on the presence of a significant difference in effect on
neurocognitive assessments of the different classes of medication, while the within
groups paradigm was used to examine the effect of treatment in the clinic within each
cohort (See Appendix A Tables 8 through 10) (Hair et al., 2006).
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CHAPTER VIII
RESULTS

Pearson Correlational Analyses
NOTE: The following Pearson Correlational Analyses were conducted largely as a
preliminary survey of the data. Some of the sets of comparisons that are described below
were not followed up in the later analyses. This decision was largely theoretical. The
primary focus of this investigation was to assess the effect of opioids and
benzodiazepines on DS and DSST, therefore in the later and more complicated analyses
the study focused on the comparison of the change variables and did not address the
admission v admission and discharge v discharge comparisons made in this initial survey.
Cohort 1 (Neither opioids or benzodiazepines). As can be seen in Appendix A Table 1,
Admission BDI was found to correlate directly with Admission PDI (r = 0.394, p<0.01,
N = 64) as well as Admission Pain Intensity (r = 0.268, p<0.05, N = 74). Furthermore,
Admission PDI was found to directly correlate with Admission Pain Intensity (r = 0.632,
p<0.01, N = 65). Interestingly, as has been observed in the literature, Admission Pain
Intensity was found to indirectly correlate with both Admission DSST raw score and
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Admission DSST scaled score (r = -0.321, p<0.01, N = 75; and r = -0.307, p<0.01, N =
75, respectively).
Also shown in Appendix A Table 1, Discharge BDI was shown to correlate
positively with Discharge PDI and Discharge Pain Intensity (r = 0.366, p<0.01, N=76;
and r = 0.400, p<0.01, N=78 respectively). Discharge Pain Intensity was also shown to
correlate positively with Discharge PDI (r = 0.553, p<0.01, N=79).
Finally, as also seen in Appendix A Table 1 ∆ Pain Intensity was found to directly
correlate with ∆ BDI and ∆ PDI (r = 0.351, p<0.01, N=71; and r = 0.470, p<0.01, N=62,
respectively).
Cohort 2 (Opioids only). As can be seen in Appendix A Table 2, Admission BDI was
found to directly correlate with Admission PDI (r = 0.584, p<0.01, N=67). Admission
Pain Intensity was also found to correlate positively with Admission PDI (r = 0.312,
p<0.05, N=67).
Also shown in Appendix A Table 2, Discharge BDI correlated directly with
Discharge PDI and Discharge Pain Intensity (r = 0.293, p<0.05, N=73; and r=0.291,
p<0.05, N=76). Also Discharge PDI was found to correlate positively with Discharge
Pain Intensity (r = 0.610, p<0.01, N=73).
Finally, as also seen in Appendix A Table 2 ∆ PDI was shown to directly correlate
with ∆ BDI , ∆ Pain Intensity, ∆ DS raw score, and ∆ DS scaled score (r = 0.548, p<0.01,
N=63; r = 0.528, p<0.01, N=62; r = 0.281, p<0.05, N63; and r = 0.259, p<0.05, N=63,
respectively).
Cohort 3 (Benzodiazepines only). As can be seen in Appendix A Table 3, Admission BDI
was found to directly correlate with Admission PDI (r = 0.470, p<0.05, N=18).
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Also shown in Appendix A Table 3, Discharge PDI was found to correlate
positively with Discharge Pain Intensity (r = 0.680, p<0.01, N=21).
Finally, as also seen in Appendix A Table 3 ∆ PDI correlated directly with ∆ Pain
Intensity ( r = 0.561, p<0.05, N=17); and indirectly ∆ DSST raw score, and ∆ DSST
scaled score (r = -0.498, p<0.05, N=17; and r = -0.510, p<0.05, N=17). Also ∆ BDI was
found to negatively correlate with both ∆ DSST raw score and ∆ DSST scaled score (r =
-0.735, p<0.01, N=21; and r = -0.745, p<0.01, N=21).
Cohort 4 (Both opioids and benzodiazepines). As can be seen in Appendix A Table 4,
Admission BDI correlated positively with Admission PDI (r = 0.403, p<0.05, N=29). It
was also found to negatively correlate with: Admission DS raw score, Admission DS
scaled score, Admission DSST raw score, and Admission DSST scaled score (r = -0.404,
p<0.05, N=38; r = -0.397, p<0.05, N=38; r = -0.414, p<0.01, N=38; r = -0.400, p<0.05,
N=38, respectively). Admission PDI was shown to correlate directly with Admission
Pain Intensity (r = 0.610, p<0.01, N=30), and negatively with: Admission DS raw score,
and Admission DS scaled score (r = -0.389, p<0.034, N=30; r = -0.370, p<0.05, N=30,
respectively). Furthermore, Admission Pain Intensity was found to correlate indirectly
with Admission DS raw score and Admission DS scaled score (r = -0.549, p<0.01, N=34;
r = -0.519, p<0.01, N=34, respectively).
Also shown in Appendix A Table 4, Discharge BDI was shown to correlate
directly with Discharge PDI (r = 0.457, p<0.01, N=38), and indirectly with Discharge
DSST Scaled score (r = -0.325, p<0.05, N=38). Additionally, Discharge PDI was found
to correlate positively with Discharge Pain Intensity (r = 0.598, p<0.01, N=37), and
negatively with Discharge DSST Scaled score (r = -0.395, p<0.05, N=37).
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Finally, as also seen in Appendix A Table 4 ∆ BDI was found to correlate directly
with ∆ PDI (r = 0.479, p<0.01, N=29), and indirectly with: ∆ DS Scaled score, ∆ DSST
Raw score, and ∆ DSST Scaled score (r = -0.399, p<0.05, N=38; r = -0.424, p<0.01,
N=38; and r = -0.344, p<0.05, N=38, respectively).
Cohort 5 (Union of Cohorts 1 through 4). As can be seen in Appendix A Table 5,
Admission BDI was found to have a positive correlation with both Admission PDI as
well as Admission Pain Intensity (r = 0.478, p<0.01, N=178; and r = 0.212, p<0.01,
N=202, respectively). Admission Pain Intensity was also found to correlate positively
with Admission PDI (r = 0.450, p<0.01, N=180), and negatively with: Admission DS
Raw score, and Admission DSST Raw score (r = -0.159, p<0.05, N=205; and r = -0.170,
p<0.05, N=205, respectively).
Also shown in Appendix A Table 5, Discharge BDI correlated directly with
Discharge PDI as well as Discharge Pain Intensity (r = 0.352, p<0.01, N=208; and r =
0.285, p<0.01, N=213, respectively). Furthermore, Discharge PDI correlated positively
with Discharge Pain Intensity (r = 0.596, p<0.01, N=210), and negatively with Discharge
DSST Raw score (r = -0.162, p<0.05, N=210).
Finally, as also seen in Appendix A Table 5 ∆ BDI was shown to correlate directly
with ∆ PDI as well as ∆ Pain Intensity (r = 0.382, p<0.01, N=170; and r = 0.269, p<0.01,
N=195, respectively), and negatively with ∆ DSST Raw score and ∆ DSST Scaled score
(r = -0.240, p<0.01, N=213; and r = -0.201, p<0.01, N=213, respectively). Additionally,
∆ PDI was shown to vary directly ∆ Pain Intensity (r = 0.519, p<0.01, N=171).

45

Hierarchical Multiple Regression Analyses
Hierarchical Multiple Regression Analysis I: Confound Effects in each Cohort. As shown
in Appendix A Table 6, results of the regressions were independent of entry order of the
IVs (∆ BDI, ∆ PDI, and ∆ Pain Intensity). In Cohort 1 (no opioids or benzodiazepines),
none of the confounding variables were found to significantly contribute to the variances
of either ∆ DS Scaled score or ∆ DSST scaled score. Only Cohort 4 (Both opioids and
benzodiazepines) demonstrated a significant contribution from any of the confounding
variables to the variance of ∆ DS Scaled score. This significant confound was found to be
∆ BDI. The exact level of significance achieved varied between the three entry paradigms
but was always in the range of 0.01<p<0.05. The exact values can be found in Appendix
B Tables 4.1 through 4.3. Cohorts 2 through 5 all demonstrated a significant contribution
of ∆ BDI to the variance of ∆ DSST Scaled score (again 0.01<p<0.05, approx p=0.02; for
exact values please see Appendix B Tables 2.4 through 2.6, 3.4 through 3.6, 4.4 through
4.6, and 5.4 through 5.6.
Hierarchical Multiple Regression Analysis II: Cohort Membership Effects. As
summarized in Appendix A Table 7 and shown in detail in Appendix B Tables 6.1 through
6.8, when Cohort Membership was dummy coded and entered into the regression analysis
as an IV block two pieces of information became apparent: 1. Factoring out Cohort
Membership did not effect the significances of the confounding variables examined in the
last section – ∆ BDI still contributed a significant part of the variance of ∆ DSST Scaled
score; 2. Cohort Membership did not significantly contribute to the variances of either
DV, moreover this result was independent of the entry order of the IVs.
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Mixed 2-way ANOVA
As shown in Appendix A Tables 9 and 10, the within-subjects, or repeated
measures, ANOVA demonstrated that treatment in the CC-CPRC was correlated with
improvements in both measures of neurocognitive ability. The significance of the
relationship of treatment in the CC-CPRC to improvement in DS Scaled score was
however, not as pronounced (F = 6.48, p = 0.012) as that seen in the relationship to
improvement

in

the

DSST

Scaled

score

(F

=

496.22,

p = 4.31E-58). Additionally, the between-groups ANOVA demonstrated a lack of
significance of Cohort Membership in determining improvements in outcome measures.
For DS Scaled Score the between-groups ANOVA found an F value of 0.16 and a p value
of 0.92 for Cohort Membership, thus demonstrating a lack of effect of this variable on DS
Scaled score change. For DSST Scaled Score the between-groups ANOVA found an F
value of 1.06 and a p value of 0.37 for Cohort Membership, thus demonstrating a lack of
effect of this variable on DSST Scaled score change as well. Lastly, within-subjects
contrast analyses examining either DV demonstrated little crossover between treatment
and cohort membership (DS Scaled score tx * Cohort: F = 0.77, p = 0.51; DSST Scaled
score tx * Cohort: F = 0.44, p = 0.72).
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CHAPTER IX
DISCUSSION

Pearson Correlational Analyses.
As mentioned earlier, this series of analyses was used to demonstrate areas of
interest for future research. This study was designed to address the effects of withdrawal
of opioids and/or benzodiazepines on two neurocognitive measures, Digit Span (DS) and
the Digit Symbol Substitution Test (DSST), as such the more involved analyses which
follow were confined to the change data (port-treatment minus pre-treatment) for all
variables considered. The decision to confine the remaining analyses was largely
theoretical; however, the correlational data did suggest interesting relationships in this
area.
As shown in Appendix A Tables 1 through 5, all five cohorts demonstrated a
direct correlation between ∆ Pain intensity and ∆ PDI. This is entirely expected as
perceived reduction in pain intensity should result in reduction in functional impairment.
Moreover, this relationship was significant with a p<0.01 (Appendix A Tables 1, 2, 4, and
5) in every cohort with the exception of cohort 3, the benzodiazepine only cohort. In this
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cohort the p value obtained was 0.019 (Appendix A Table 3), still a significant value. In
fact, it is highly likely that if a larger sample size for this specific cohort were obtained
(this cohort had an N of 17) the p value may be lowered to less than 0.01.
Several of the cohorts (cohorts 2, 4, and 5) also demonstrated a significant
(p<0.01) direct relationship between ∆ BDI and ∆ PDI (Appendix A Tables 2, 4, and 5).
Again, this is not surprising as a reduction in BDI score reflects an improvement in mood
which one would expect to be reflected in a reduction in functional impairment pursuant
to the idea that less depression facilitates functionality. While this result was not obtained
in cohort 3 this may simply again reflect a limitation of the methodology and sample size
of this cohort (N=17) (Appendix A Table 3). The lack of a relationship in cohort 1, the no
opioid no benzodiazepine group (N=61, see Appendix A Table 1) may reflect a selection
bias in this cohort. Individuals in this cohort had the lowest mean admission BDI;
therefore in this group the symptomatology found at admission to treatment may be less
related to emotional state. Additionally, the effect of changes in BDI in this group may be
less pronounced than in the other cohorts. Furthermore, this data offers an interesting
glimpse into an area requiring further study, namely that patients not on opioids or
benzodiazepines may be less depressed than those who are receiving one or both of these
classes of medication. However, it is not possible to estimate, based on the data reported
here, whether this relationship reflects that patients who are less depressed are less likely
to receive opioids and benzodiazepines or whether patients receiving theses classes of
medication are more likely to be depressed.
Interestingly it is cohorts 3, 4, and 5 which demonstrate the primary finding borne
out in each cohort in the later analyses: the relationship between ∆ BDI and ∆ DSST
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(Appendix A Tables 3, 4, and 5). The negative direction of the correlation is an artifact of
the analysis method. ∆ BDI was calculated as post-treatment minus pre-treatment values.
The vast majority of patients present a lower BDI after treatment than at onset of
treatment. This reflects an improvement in mood. Therefore the negative correlation
between ∆ BDI and ∆ DSST is actually describing the relationship of improving mood to
improving DSST scaled score, i.e. neurocognitive functioning.
Finally, the correlational studies suggest several areas for further research. For
example, in addition to the relationship of the ∆ BDI to ∆ PDI already discussed, most of
the cohorts reflect a relationship between BDI and PDI at admission, and discharge as
well. This is not surprising and reinforces the connection between mood and
functionality, an area of ongoing research and much clinical interest. In fact, the presence
of this relationship in these analyses serves to reinforce the validity of the measures and
methods used herein. An additional area of interest borne out in the correlational analyses
is the sensitivity of DS versus DSST in assessing improvement in neurocognitive
functioning. As will be seen in the additional analyses discussed below, DSST was
shown to be much more sensitive to the variables assessed here than DS. As seen in the
introduction, much research has utilized these measures and a further study elucidating
the differences in their respective sensitivities and specificities may be of interest.

Hierarchical Multiple Regression Analyses
This strategy elucidated many interesting relationships. As presented earlier and
shown in Appendix A Table 6, results of the regressions were independent of entry order
of the IVs (∆ BDI, ∆ PDI, and ∆ Pain Intensity). This indicates that although theoretically
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these confounds are related, and may even correlate they do not significantly covary. In
other words, the same significance values are obtained for each block of IV independent
of which block comes before or after.
The regression analysis also reinforced the lack of relationship, in cohort 1 (no
opioids or benzodiazepines), between the confounding variables and either the ∆ DS
Scaled score or the ∆ DSST scaled score. This was alluded to in the correlational
analyses just discussed, and again may reflect an inherent quality of the individuals in
this cohort. It is possible that these individuals possess personality traits which result in
lower incidences of or levels of depressive symptoms. This in turn alters their overall
symptomatology and results in no need for medication treatment with opioids or
benzodiazepines. Alternatively, as described in the section above discussing the
relationship observed in the correlational analyses, individuals who are not on either
opioid or benzodiazepine therapy maybe less depressed simply because they are not
taking these medications. Again, the casual nature of this relationship is beyond the scope
of this study. As noted later, however, these individuals still benefit from treatment in the
clinic as all cohorts demonstrated significant improvement in DSST scaled score;
moreover this improvement was not merely demonstrated across all cohorts, but was in
fact independent of cohort membership.
One of the most significant results to emerge from this study is exemplified by
cohorts 2 through 5, all of which demonstrated a significant contribution of ∆ BDI to the
variance of ∆ DSST Scaled score (for exact values please see Appendix B Tables 2.4
through 2.6, 3.4 through 3.6, 4.4 through 4.6, and 5.4 through 5.6). Again, this is not
surprising as it is a long held theory that mood greatly effects functioning either physical
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or psychological. Of note here is although, as just described, cohort 1 did not on its own
demonstrate this relationship, cohort 5 – the union of cohorts 1 through 4, did
demonstrate it with a p value of approximately 0.007. This may be viewed as a dilution of
the population of cohort 1 into a much larger population which in the absence of cohort 1
may show an even more significant effect of ∆ BDI, or it may reflect a real relationship
dormant in cohort 1 which has gone unseen due to limits of sample size and power.
The correlational analysis discussed above alluded to a lower sensitivity of DS as
compared to that of DSST for the variables and or population studied here. The
regression analysis reinforced this idea as only Cohort 4 (Both opioids and
benzodiazepines) demonstrated a significant contribution from any of the confounding
variables to the variance of ∆ DS Scaled score. As with ∆ DSST the significant confound
was found to be ∆ BDI. The exact significance values can be found in Appendix B Tables
4.1 through 4.3. Although not required or expected by theory, it is not a surprise that the
confound discovered to consistently have the strongest relationship to DSST, apparently
the more sensitive test, is the first to demonstrate a relationship with DS, the apparently
less sensitive test. It is of course entirely possible that DS can be less sensitive overall
than DSST while simultaneously displaying greater sensitivity to a different variable or
variables than DSST.
When cohort membership was dummy coded and examined as an IV it did not
affect the significances of the three confounding variables already examined in the last
section. ∆BDI still contributed a significant part of the variance of ∆ DSST Scaled score.
No other confound was found significant, and ∆ DSST was still more sensitive than ∆ DS
to the variables examined.
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In addressing the core questions of this study, cohort membership itself did not
significantly contribute to the variances of either DV. This result was also independent of
the entry order of the IVs. This means that although, as has been shown and will be
reinforced below, all individuals’ neurocognitive functioning was shown to improve
based on ∆ DSST Scaled score this improvement was independent of opioid or
benzodiazepine status at onset of treatment. In other words, while individuals taking these
medications improved their cognitive function, this improvement was not significantly
different than that observed by those who were not taking these medications. All
individuals studied benefited from treatment regardless of the presence of opioids or
benzodiazepines in their intake treatment regimens.

Mixed 2-way ANOVA
The Mixed 2-way ANOVA served to address two fundamental questions. First,
does treatment in the clinic result in improved neurocognitive function as measured by
DS or DSST. Second, does cohort membership, i.e. opioid and/or benzodiazepine status
effect the change seen in DS or DSST.
As presented above and shown in Appendix A Tables 9 and 10, the withinsubjects, or repeated measures, ANOVA demonstrated that treatment in the CC-CPRC
was correlated with improvements in both measures of neurocognitive ability. The
significance of the relationship of treatment in the CC-CPRC to improvement in DS
Scaled score was however, not as pronounced (F = 6.48, p = 0.012) as that seen in the
relationship to improvement in the DSST Scaled score (F = 496.22, p = 4.31x10-58). This
is consistent with the differences seen in sensitivities in the prior two analysis strategies,
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and simultaneously reinforces the benefit and effectiveness of treatment in all individuals
studied.
The between-groups ANOVA demonstrated a lack of significance of Cohort
Membership in determining changes in either DS or DSST. This reinforces the results of
the regression analysis just discussed. All individuals, regardless of the presence of
opioids or benzodiazepines in their pre-treatment regimens benefit from treatment. Those
taking one or both of these medications do not show significantly different changes in
their DS or DSST when compared to those who have not taken either class of medication.
Their improvements are significant but are not significantly different from the
improvements of those who have not taken medications from these two classes.
Finally, the within-subjects contrast analyses examining either DV (DS or DSST)
demonstrated little crossover between treatment and cohort membership (DS Scaled score
tx * Cohort: F = 0.77, p = 0.51; DSST Scaled score tx * Cohort: F = 0.44, p = 0.72). This
indicates that the results observed for treatment and cohort membership are not the result
of covariance with each other, but rather are true independent results.
The study presented here has several important, take-home messages. First, based
on the results of this study, withdrawal from opioid and/or benzodiazepine therapy does
not result in a measurable change in neurocognitive functioning measured by DS or
DSST. Second, a relationship of Pain Intensity to level of functionality has been shown.
This is well known, and its finding here reinforces the validity of the methods used
herein. Third, there is confirmation that mood greatly effects functioning both physically
– as indicated by the BDI/PDI relationship alluded to by the correlational analyses, and
psychologically – as borne out by the ∆ BDI/ ∆ DSST relationship found in both the
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correlational and hierarchical linear regression analyses. Again, the relationship of mood
to functionality, like that of pain intensity to functionality, is well established and its
presence in these results reinforces the validity of the methods used. Fourth, changes in
mood were found to be the most significant predictor of changes in DSST Scaled score.
Fifth, Interdisciplinary treatment of chronic pain provides measurable benefit to all
individuals regardless of pre-treatment medication status.
In considering potential questions raised by this study two can be readily drawn
from the analysis and discussion. First, questions are raised about the sensitivity and
therefore utility of DS as opposed to DSST in studies such as these with populations such
as this. Although these measures have been used in the literature often and the disparity
in sensitivities observed here may be due to such things as a lack of power, further study
in this area may be warranted. Second, the lower initial BDIs in cohort 1 combined with
the lack of significance of the effect of ∆ BDI on ∆ DSST when confined to this cohort
raises questions about the potential for inherent differences in the characteristics of the
population in this sample. Perhaps they possess personality characteristics, coping
mechanisms or support structures which allow them to: be less prone to depression;
experience less disability from chronic pain; or perhaps opioids or benzodiazepines
increase the incidence of depressive symptoms. A better understanding of the
characteristics of this group and a determination if they are intrinsically different than the
rest of the population studied here could provide useful insights that may be translated to
valuable treatment methods for other individuals.
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Table 1: Pearson Correlational Analysis: Cohort 1
Paradigm Description and Results Summary
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Table 2: Pearson Correlational Analysis: Cohort 2
Paradigm Description and Results Summary
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Table 3: Pearson Correlational Analysis: Cohort 3
Paradigm Description and Results Summary

91

Appendix A

Table 4: Pearson Correlational Analysis: Cohort 4
Paradigm Description and Results Summary
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Table 5: Pearson Correlational Analysis: Cohort 5
Paradigm Description and Results Summary
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Table 6: Hierarchical Multiple Regression Analysis I: Confound Effects in each Cohort
Paradigm Description and Results Summary
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Table 7: Hierarchical Multiple Regression Analysis II: Cohort Membership Effects
Paradigm Description and Results Summary
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Table 8: Graphic Description of MANOVA strategies
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Table 9: MANOVA results for Digit Span
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Table 10: MANOVA results for Digit Symbol Substitution Test
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